|
You are here: Home: Meet The Professors Vol. 1 2004: Faculty and affiliations
Faculty and Affiliations
 |
Howard A Burris III, MD
Director of Drug Development, Sarah Cannon Cancer Center
Nashville Tennessee |
 |
Harold J Burstein, MD, PhD
Assistant Professor of Medicine, Harvard Medical School Breast Oncology Center, Dana-Farber Cancer Institute
Boston, Massachusetts |
 |
Maria Theodoulou, MD
Associate Attending Physician
Memorial Sloan-Kettering Cancer Center
New York, New York |
 |
Charles L Vogel, MD, FACP
Medical Director, Cancer Research Network
Plantation, Florida |
Community Panel
Laurence Bilsky, MD
Medical Oncology Associates of Long Island, PC
Syosset, New York
Neal M Friedberg, MD HemOnCare PC Brooklyn, New York
Anna Gattani, MD
Mount Sinai Hospital
Brooklyn, New York
Paul AC Greenberg, MD, FACP
Greenberg Breast Cancer Research Foundation Inc Brooklyn, New York |
Stephen M Lichter, MD, FACP
Associate Director, Hematology/Oncology Beth Israel Hospital, Kings Highway Division
Brooklyn, New York
Mark D Lipshutz, MD, FACP
Chairman, Department of Hematology/Medical Oncology Good Samaritan Hospital Medical Center
Bay Shore, New York
Dennis A Lowenthal, MD
Co-Chairman of the Cancer Committee, Overlook Hospital Summit, New Jersey |
Yelena Novik, MD, FACP
New York University Cancer Institute
New York, New York
Lakshmi Rajdev, MD, MS
Montefiore Medical Center Bronx, New York
Ranjana Tavorath, MD
Saint Barnabas Medical Center
Livingston, New Jersey
Richard S Zelkowitz, MD
Chief, Section Hematology/Oncology Norwalk Hospital
Norwalk, Connecticut |
FACULTY DISCLOSURES
As a provider accredited by the ACCME, it is the policy of Research To Practice Inc to require the disclosure of any significant financial interest or any other relationship the sponsor or faculty members have with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following:
|
| Howard A Burris III, MD |
Grants/Research Support: Aventis Pharmaceuticals Inc, Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc Consultant: Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline Honorarium: Aventis Pharmaceuticals Inc, Bristol-Myers Squibb Company, Eli Lilly & Company, Genentech BioOncology, GlaxoSmithKline |
| Harold J Burstein, MD, PhD |
Grants/Research Support: Aventis Pharmaceuticals Inc, Genentech BioOncology, GlaxoSmithKline |
| Maria Theodoulou, MD |
Grants/Research Support: Elan Corporation, Roche Laboratories Inc |
| Charles L Vogel, MD, FACP |
Grants/Research Support, Consultant and Honorarium: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eli Lilly & Company, EMD Pharmaceuticals Inc, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Ortho Biotech Products LP, Pfizer Inc, Roche Laboratories Inc |
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
|
|
